Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simnotrelvir + Ritonavir in Mild/Common COVID-19
NCT05373433Phase 3Unknown
- Sponsor
- Simcere Pharmaceutical Group
- Start
- May 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of simnotrelvir in coronavirus disease 2019 (COVID-19), sponsored by Simcere Pharmaceutical Group. Status: unknown.
02
Drugs
simnotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05373433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05373433.